Visiting Experts AMA: Yujiro Hata (WG'01) - CEO of IDEAYA Biosciences

March 21, 2024 at 12:00pm - 1:00pm
Yujiro Hata (WG'01) is the President and CEO of IDEAYA Biosciences and has over 20 years of experience in healthcare.
Yujiro is an entrepreneur with over 20 years of experience building companies that have delivered innovative therapies to patients. In June 2015, he launched and incorporated IDEAYA Biosciences as its first employee and Chief Executive Officer and led the company’s IPO in May 2019 (NASDAQ: IDYA). From 2015 to 2018, he served as an Executive-in-Residence at 5AM Ventures. From 2014 to August 2015, he served as Chief Operating Officer at Flexus Biosciences, which he led through its acquisition by Bristol-Myers Squibb in April 2015, and then served as Chief Operating Officer at FLX Bio (renamed RAPT Therapeutics, NASDAQ: RAPT), a spinout of Flexus Biosciences. From 2010 to 2014, including through the approvals of Kyprolis® and Stivarga® and its acquisition by Amgen in October 2013, he was Vice President, Corporate Development and Strategy at Onyx Pharmaceuticals (NASDAQ: ONXX), where he served as Head of Strategy and Strategic Asset Management, and Head of Transactions. From 2002 to 2010, Yujiro served as Vice President, Business Development, Senior Vice President, Business Development, and Chief Business Officer at Enanta Pharmaceuticals (NASDAQ: ENTA), which discovered the protease inhibitors contained in Viekira Pak and Mavyret™, both of which received Breakthrough Therapy designation and approval by the FDA. He earlier served in roles at McKinsey, ImClone and Columbia Medical School.

Yujiro obtained his M.B.A. at the University of Pennsylvania where he was a Henry J. Kaiser recipient and was awarded 1st prize at the 2nd Annual Wharton Business Plan competition out of 226 business plans. He obtained his B.A. in chemistry at Colorado College and did undergraduate studies in chemistry and biology at Oxford University. He served on the Board of Directors at Xencor (NASDAQ: XNCR) from 2015 to 2022 and serves on the Board of Directors at Enanta Pharmaceuticals (NASDAQ: ENTA) and as Board Member at the Moores Cancer Center at the University of California, San Diego.